The Drug Safety Reform: Actions and Implications
ATLANTA (PRWEB) March 8, 2007
"The DIA Annual Meeting has chronicled events of profound impact to the development of medicines; has offered a forum to innovators, critics, thought leaders, regulators, and students; has attracted and nurtured an ever-expanding multinational constituency; and has become the must-attend event of the year," said Alberto Grignolo, PhD, DIA Annual Meeting Program Chair and corporate vice president and general manager of the Drug Development Consulting Practice in PAREXEL Consulting.
2007 Hot Topics
DIA has never been more optimistic about its ability to facilitate open discussion on the pharmaceutical industry's hottest topics, and this year is no exception. In addition to the traditional tracks that have made the DIA Annual Meeting the event of the year for the pharmaceutical and related industries, this year's DIA Annual Meeting boasts 27 tracks featuring sessions on the latest hot topics in pharmaceutical drug development, including:
-- Adaptive Trials/Adaptive Methods
-- U.S. FDA's Critical Path Initiatives
-- Global Clinical Trials
-- Personalized Medicine
DIA's Annual Meeting provides the perfect venue for sharing information that optimizes the process of pharmaceutical drug development and lifecycle management, discussing knowledge-based and technology-driven pharmaceutical solutions, and blending pharmaceutical professional cross-functional learning with robust networking opportunities. Throughout the week, DIA conference participants will benefit from nearly 400 regular, plenary, and tutorial sessions across 27 content-area tracks, more than 1,000 speakers, and over 450 exhibitors showcasing the pharmaceutical industry's latest products and services--geared to DIA attendees of all professional, degree, and functional responsibility levels. In addition, DIA attendees can maximize their DIA Annual Meeting experience by attending pre-conference tutorials on June 16-17.
-- The DIA Plenary Session on Monday, June 18 will feature a keynote address by Dr. Julie Gerberding, director for the Centers for Disease Control and Prevention (CDC) and administrator of the Agency for Toxic Substances and Disease Registry (ATSDR).
-- Dora L. Hughes, MD, MPH, legislative assistant, Senator Barack Obama's Office, U.S., will address "Personalized Medicine and Personalized Drug Development: Case Studies and Progress to Date" on June 18.
-- This year's DIA Annual Meeting will feature the first Multi-track Plenary Session, "The Drug Safety Reform: Actions and Implications," on Tuesday, June 19. The panel will discuss the Institute of Medicine's recommendations for improvements to the U.S. drug safety system, as well as actions of the FDA, Congress, PhRMA, and other key players. The discussion will include an update on the current status of the Prescription Drug User Fee Act and other legislative initiatives. Invited speakers include representatives from the offices of Senators Edward Kennedy and Michael B. Enzi.
-- The DIA 43rd Annual Meeting, in its continued efforts to reach out to up-and-coming pharmaceutical professionals, will include a Student Forum on June 19. Students will learn about DIA's student initiative program, employment opportunities in clinical research, and developing a resume.
Finding solutions to pharmaceutical industry challenges requires comprehensive approaches that draw on the expertise of international and multidisciplinary thought leaders from academia, regulatory agencies, and private industries. Representatives from more than 65 countries will be in attendance at this year's DIA Annual Meeting, including:
-- Academic institutions from Brazil, Canada, Denmark, India, Japan, Korea, Panama, Taiwan, Tokyo, Europe, and US
-- Government agencies from Argentina, Australia, Belgium, Canada, Europe, India, Japan, Korea, South, Africa, Taiwan, and United States
-- Representatives from FDA, MHRA, WHO, Health Canada, CDE-Taiwan, EMEA, PMDA-Japan, SFDA-China, and Centers for Disease Control and Prevention (CDC)
Boasting an exhibit hall of more than 450 exhibitors, the DIA Annual Meeting provides the perfect one-stop shopping opportunity for companies to showcase their products and services to pharmaceutical professionals who use them every day.
"Whether for the first time or the 43rd, DIA attendees will reap the benefits of the imagination, dedication, and intellectual diversity of those who have labored to craft a program of vast breadth and complexity to stimulate, engage, challenge, and inform," noted Grignolo. "This year's Program Committee has designed an event that is timely, topical, and transforming."
Register online at http://www.diahome.org and click on the Annual Meeting icon. Media interested in attending the event or arranging for pre- or post-event interviews should contact Amy Singer Douglass, Toplin & Associates, Inc., at (215) 793-4666, ext.119 or Amysd@toplin.com.
About the Drug Information Association (DIA) (http://www.diahome.org)
The DIA serves more than 18,000 professionals in the biotechnology, pharmaceutical and regulatory industries worldwide. Through its domestic and international meetings, training courses, workshops and webinars, DIA provides a neutral global forum for the exchange of information critical to the advancement of the drug discovery and lifecycle management processes. Headquartered in Horsham, Pa., USA, and with offices in Basel, Switzerland and Tokyo, Japan, the Association is led by its volunteer-based board of directors and executive management team. For more information, visit http://www.diahome.org/ or call 215-442-6100.
Optimized by Newsforce